Dubai, October 18, 2024 – Longenesis, Latvian digital health tech startup, has secured a monumental victory at the Supernova Challenge 2.0 in Dubai, winning the top prize of $100,000. As one of the most prestigious global startup competitions, Supernova Challenge 2.0, held at the Dubai World Trade Centre, gathered over 1,800 startups from more than 50 countries, showcasing transformative ideas from all fields.
Competing against top innovators, Longenesis captivated the judges with its revolutionary approach to health data engagement, designed to accelerate patient involvement and access to life-saving therapies. “This victory highlights the growing importance of health data solutions on a global scale,” remarked Emil Syundyukov, CEO and Co-Founder of Longenesis. “We are excited to expand our impact, particularly in the Gulf region, which we believe is central to the future of digital health innovations.”
Longenesis platform enables secure and compliant data access for healthcare research, addressing the complex landscape of global data-sharing and patient privacy. This victory signals Longenesis increasing prominence in digital health and its readiness to take on the global market.
Since 2020, Longenesis has been supporting M42 in the execution of the UAE's national genome initiative, the Emirates Genome Program with solutions in patient engagement and dynamic consent. Although Longenesis has already been working with partners in the UAE for almost 5 years this victory only emphasises that there are many other opportunities available.
Competing against top innovators, Longenesis captivated the judges with its revolutionary approach to health data engagement, designed to accelerate patient involvement and access to life-saving therapies. “This victory highlights the growing importance of health data solutions on a global scale,” remarked Emil Syundyukov, CEO and Co-Founder of Longenesis. “We are excited to expand our impact, particularly in the Gulf region, which we believe is central to the future of digital health innovations.”
Longenesis platform enables secure and compliant data access for healthcare research, addressing the complex landscape of global data-sharing and patient privacy. This victory signals Longenesis increasing prominence in digital health and its readiness to take on the global market.
Since 2020, Longenesis has been supporting M42 in the execution of the UAE's national genome initiative, the Emirates Genome Program with solutions in patient engagement and dynamic consent. Although Longenesis has already been working with partners in the UAE for almost 5 years this victory only emphasises that there are many other opportunities available.